GE Healthcare Inc

GE HealthCare’s Q2 earnings show revenue growth, EPS beat, and a robust order book, while a new interim CFO underscores continuity amid shifting healthcare data and reimbursement regulations.

GE HealthCare Q2 2026: 6% revenue rise, 16% EPS boost, and interim CFO George Newcomb’s leadership keeps investors confident amid industry shifts.

GE HealthCare’s latest officer‑owned share purchase reveals confidence and highlights the firm’s focus on cost‑effective, AI‑driven tech to meet shifting value‑based care demands.

GE Healthcare Technologies insider purchase signals confidence; strong AI‑driven imaging, R&D growth, supply‑chain resilience, and FDA pre‑cert boost future prospects.

Insider buys at GE HealthCare reveal executive confidence, yet analysts trim targets and a fiduciary‑duty probe looms—read the full impact on stock and strategy.

GE Healthcare Q1 earnings miss hits stock; revenue up 3.8% while margins shrink. Analysts weigh inflation, supply‑chain, and AI‑driven growth prospects.

GE Healthcare expands its $35 M BARDA partnership to develop AI‑enabled ultrasound, speeding trauma diagnostics, cutting costs and easing operator demands.

GE Healthcare’s latest earnings beat, analyst lift, and institutional moves reveal a cautious outlook amid regulatory and AI‑driven competition, highlighting risks and growth prospects.

GE Healthcare’s $105 M Indonesian CT scanner deal and renewed Vaso partnership illustrate a strategic push into Southeast Asia’s growing diagnostic imaging market, backed by debt, equity and AI‑enabled tech to drive ROI and NCD screening.

GE HealthCare unveils its next‑generation SIGNA™ MRI platform at RSNA 2025, showcasing advanced image quality, AI‑powered workflows, and regulatory progress for precision‑care imaging.